Hypothalamic Obesity Clinical Trial
Official title:
A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity
Verified date | May 2024 |
Source | Rhythm Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for up to 60 weeks.
Status | Enrolling by invitation |
Enrollment | 120 |
Est. completion date | April 16, 2025 |
Est. primary completion date | April 16, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years and older |
Eligibility | Key Inclusion Criteria: 1. Documented evidence of acquired hypothalamic obesity (HO) 2. Age 4 years and older 3. Weight gain associated with the hypothalamic injury and a BMI of =30 kg/m2 for patients =18 years of age or BMI =95th percentile for age and sex for patients 4 to <18 years of age 4. Agree to use a highly effective form of contraception throughout the study and for 90 days after the study Key Exclusion Criteria: 1. Diagnosis of Prader-Willi syndrome (PWS) or Rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, neuroendocrine tumor syndrome (ROHHADNET) 2. Weight loss >2% in the previous 3 months for patients aged =18 years or >2% reduction in BMI for patients aged 4 to <18 years 3. Bariatric surgery or procedure within last 2 years 4. Diagnosis of severe psychiatric disorders; any suicidal ideation, attempt or behavior 5. Current, clinically significant pulmonary, cardiac, metabolic, or oncologic disease 6. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion) 7. History or close family history of skin cancer or melanoma 8. Participation in any clinical trial with an investigational drug/device within 3 months prior to the first trial dose 9. Previously enrolled in a clinical trial involving setmelanotide or any previous exposure to setmelanotide 10. Inability to comply with once daily (QD) injection regimen 11. If female, pregnant and/or breastfeeding 12. Patients with obesity attributable to other genetic or syndromic conditions (eg, PPL [POMC, PCSK1, LEPR, collectively], BBS) prior to the hypothalamic injury. 13. If receiving hormone replacement therapy, dose has remained stable for at least 2 months before Screening Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Canada | CIUSSS de l'Estrie-CHUS Endocrinology | Sherbrooke | Quebec |
Canada | Hospital for Sick Children | Toronto | Ontario |
Canada | BC Children's Hospital | Vancouver | British Columbia |
Germany | Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH | Hamburg | |
Germany | Medicover Neuroendokrinologie | München | |
Germany | Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin | Ulm | |
Japan | Nagano Children's Hospital | Azumino City | Nagano |
Japan | Chiba University Hospital | Chiba-shi | Chiba |
Japan | Nagoya City University Hospital | Nagoya | Aichi |
Netherlands | Prinses Maxima Center for Pediatric Oncology | Utrecht | |
United Kingdom | Hull University Teaching Hospital | Hull | |
United Kingdom | Great Ormond Street Hospital for Children | London | |
United Kingdom | UCL Great Ormond Street Institute of Child Health | London | |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | UAN Pediatric Endocrinology | Birmingham | Alabama |
United States | Ann and Robert H. Lurie Children's Hospital | Chicago | Illinois |
United States | Ohio State Wexner Medical Center | Columbus | Ohio |
United States | University of Florida | Gainesville | Florida |
United States | University of Iowa Stead Family Department of Pediatrics | Iowa City | Iowa |
United States | Vanderbilt University School of Medicine | Nashville | Tennessee |
United States | Columbia University Irving Medical Center | New York | New York |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | Lynn Health Science Institute | Oklahoma City | Oklahoma |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | Children's Minnesota | Saint Paul | Minnesota |
United States | Rady Children's Hospital | San Diego | California |
United States | Seattle Children's Hospital, Research and Foundation - Center for Integrative Brain Research | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Rhythm Pharmaceuticals, Inc. |
United States, Canada, Germany, Japan, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean % change in BMI | From Baseline to Week 60 | ||
Secondary | Proportion of patients with =5% reduction in BMI in adult patients (=18 years of age) or a BMI Z-score reduction of =0.2 points in pediatric patients (<18 years of age) | From Baseline to Week 60 | ||
Secondary | Mean change in the weekly average of the daily most hunger score in patients =12 years old | From Baseline to Week 60 | ||
Secondary | Proportion of patients with a =2 point reduction in the weekly average of the daily most hunger score | From Baseline to Week 60 | ||
Secondary | Mean change in Symptoms of Hyperphagia total score | From Baseline to Week 60 | ||
Secondary | Proportion of patients with a =10% reduction in BMI | From Baseline to Week 60 | ||
Secondary | Mean percent change in weight in patients =18 years | From Baseline to Week 60 | ||
Secondary | Mean BMI-z score and BMI percentile reduction in patients <18 (using combined height and weight to report BMI in kg/m2) | From Baseline to Week 60 | ||
Secondary | Proportion of patients aged =4 to <18 years with =0.2-point reduction of BMI Z-score | From Baseline to Week 60 | ||
Secondary | Proportion of patients with BMI <30 kg/m2 (patients aged =18 years) or <95th percentile (patients aged <18 years) | From Baseline to Week 60 | ||
Secondary | Mean change in physical functioning score and total score for the Impact of Weight on Quality of Life-Lite (IWQOL) | From Baseline to Week 60 | ||
Secondary | Safety and tolerability of setmelanotide compared to placebo assessed by frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From Baseline to Week 60 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02849743 -
Intranasal Oxytocin in Hypothalamic Obesity
|
Phase 2 | |
Recruiting |
NCT06217848 -
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
|
Early Phase 1 | |
Withdrawn |
NCT05147415 -
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
|
Phase 2 | |
Completed |
NCT00892073 -
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
|
Phase 2 | |
Not yet recruiting |
NCT06299891 -
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
|
Phase 2 | |
Recruiting |
NCT06239116 -
A Study of RM-718 in Healthy Subjects and in Patients With HO
|
Phase 1 | |
Completed |
NCT02664441 -
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
|
Phase 3 | |
Completed |
NCT04725240 -
Open-Label Study of Setmelanotide in Hypothalamic Obesity
|
Phase 2 | |
Completed |
NCT03673813 -
A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
|
||
Not yet recruiting |
NCT06046443 -
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
|
Phase 2 | |
Withdrawn |
NCT03708913 -
Neuromodulation for Hypothalamic Obesity
|
N/A | |
Completed |
NCT01061775 -
Effects of Exenatide on Hypothalamic Obesity
|
Phase 1/Phase 2 | |
Completed |
NCT02860923 -
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
|
Phase 3 | |
Completed |
NCT00171613 -
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients
|
Phase 4 | |
Recruiting |
NCT01783717 -
Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage
|
N/A | |
Completed |
NCT05319301 -
Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
|
N/A |